148 related articles for article (PubMed ID: 31200831)
1. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.
Tsakonas G; Botling J; Micke P; Rivard C; LaFleur L; Mattsson J; Boyle T; Hirsch FR; Ekman S
Lung Cancer; 2019 Jul; 133():69-74. PubMed ID: 31200831
[TBL] [Abstract][Full Text] [Related]
2. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma.
Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
Ann Surg Oncol; 2017 Mar; 24(3):770-777. PubMed ID: 27696172
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL
Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
6. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
[TBL] [Abstract][Full Text] [Related]
7. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.
Millares L; Barreiro E; Cortes R; Martinez-Romero A; Balcells C; Cascante M; Enguita AB; Alvarez C; Rami-Porta R; Sánchez de Cos J; Seijo L; Monsó E;
Lung Cancer; 2018 Aug; 122():124-130. PubMed ID: 30032820
[TBL] [Abstract][Full Text] [Related]
9. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
Casadevall D; Gimeno J; Clavé S; Taus Á; Pijuan L; Arumí M; Lorenzo M; Menéndez S; Cañadas I; Albanell J; Serrano S; Espinet B; Salido M; Arriola E
Oncotarget; 2015 Jun; 6(18):16215-26. PubMed ID: 26041880
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
11. Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer.
Gao HF; Li AN; Yang JJ; Chen ZH; Xie Z; Zhang XC; Su J; Lou NN; Yan HH; Han JF; Wu YL
Clin Lung Cancer; 2017 Jan; 18(1):85-91. PubMed ID: 27461774
[TBL] [Abstract][Full Text] [Related]
12. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
Graziano SL; Lacas B; Vollmer R; Kratzke R; Popper H; Filipits M; Seymour L; Shepherd FA; Rosell R; Veillard AS; Taron M; Pignon JP
Lung Cancer; 2013 Oct; 82(1):149-55. PubMed ID: 23920379
[TBL] [Abstract][Full Text] [Related]
13. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
15. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
16. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
Foster CC; Rusthoven CG; Sher DJ; Feldman L; Pasquinelli M; Spiotto MT; Koshy M
Lung Cancer; 2019 Apr; 130():162-168. PubMed ID: 30885339
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
